Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuwellis Inc (NUWE)

Nuwellis Inc (NUWE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,031
  • Shares Outstanding, K 1,659
  • Annual Sales, $ 8,740 K
  • Annual Income, $ -11,170 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta -0.17
  • Price/Sales 0.50
  • Price/Cash Flow N/A
  • Price/Book 0.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 73.11
  • Growth Rate Est. (year over year) +1,266.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.02 +20.30%
on 11/24/25
2.96 -17.91%
on 11/06/25
-0.37 (-13.21%)
since 11/05/25
3-Month
2.02 +20.30%
on 11/24/25
5.23 -53.54%
on 09/15/25
-2.45 (-50.20%)
since 09/05/25
52-Week
2.02 +20.30%
on 11/24/25
70.14 -96.54%
on 01/30/25
-50.07 (-95.37%)
since 12/05/24

Most Recent Stories

More News
Nuwellis Continues Clinician-Driven Growth in Pediatric Care with a Leading Hospital in the Northeast U.S.

MINNEAPOLIS, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, announced today...

NUWE : 2.43 (-7.60%)
Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum

MINNEAPOLIS, MN, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the...

NUWE : 2.43 (-7.60%)
Nuwellis Receives Notice of Allowance of a New U.S. Patent Strengthening Vivian™ Pediatric System with Advanced Clamp Safety Technology

MINNEAPOLIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the...

NUWE : 2.43 (-7.60%)
Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025

MINNEAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the...

NUWE : 2.43 (-7.60%)
Nuwellis Appoints John L. Erb as Interim CFO

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Nuwellis...

NUWE : 2.43 (-7.60%)
Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®

ULTRA-Peds Registry, the largest multi-center dataset of its kind, shows Aquadex therapy was well-tolerated in critically ill children, a population with extremely limited treatment options Results...

NUWE : 2.43 (-7.60%)
Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration

EDEN PRAIRIE, Minn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,415,021...

NUWE : 2.43 (-7.60%)
Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment

Watch the “What This Means” segment here MINNEAPOLIS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions...

NUWE : 2.43 (-7.60%)
Nuwellis’ Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio

Awarded grant supports dedicated pediatric continuous renal replacement therapy (CRRT) device in development for patients between 2.5 and 20 kg where therapeutic options are scarce Company working...

NUWE : 2.43 (-7.60%)
Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management

MINNEAPOLIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall. The...

NUWE : 2.43 (-7.60%)

Business Summary

Nuwellis Inc. is a medical device company. It is focused on developing, manufacturing and commercializing the Aquadex SmartFlow(R) System for ultrafiltration therapy. Nuwellis Inc., formerly known as CHF Solutions, is headquartered in Minneapolis, Minn.

See More

Key Turning Points

3rd Resistance Point 2.84
2nd Resistance Point 2.75
1st Resistance Point 2.59
Last Price 2.43
1st Support Level 2.34
2nd Support Level 2.25
3rd Support Level 2.09

See More

52-Week High 70.14
Fibonacci 61.8% 44.12
Fibonacci 50% 36.08
Fibonacci 38.2% 28.04
Last Price 2.43
52-Week Low 2.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar